Design Therapeutics, Inc. Financials

Design Therapeutics, Inc. (DSGN) reported $0 in total revenue for fiscal year 2025. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

No, Design Therapeutics, Inc. (DSGN) reported a net income of -$69.8M in fiscal year 2025.

Design Therapeutics, Inc. (DSGN) reported diluted earnings per share of $-1.22 for fiscal year 2025. This represents a -38.6% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Design Therapeutics, Inc. (DSGN) had EBITDA of -$78.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

Design Therapeutics, Inc. (DSGN) has a return on equity of -32.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

Design Therapeutics, Inc. (DSGN) generated -$54.6M in free cash flow during fiscal year 2025. This represents a -25.6% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

Design Therapeutics, Inc. (DSGN) generated -$54.4M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

Design Therapeutics, Inc. (DSGN) had $226.2M in total assets as of fiscal year 2025, including both current and long-term assets.

Design Therapeutics, Inc. (DSGN) invested $193K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

Design Therapeutics, Inc. (DSGN) invested $59.1M in research and development during fiscal year 2025.

Design Therapeutics, Inc. (DSGN) had 60M shares outstanding as of fiscal year 2025.

Design Therapeutics, Inc. (DSGN) had a current ratio of 17.14 as of fiscal year 2025, which is generally considered healthy.

Design Therapeutics, Inc. (DSGN) had a debt-to-equity ratio of 0.06 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

Design Therapeutics, Inc. (DSGN) had a return on assets of -30.9% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

Based on fiscal year 2025 data, Design Therapeutics, Inc. (DSGN) had $16.9M in cash against an annual operating cash burn of $54.4M. This gives an estimated cash runway of approximately 4 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

Design Therapeutics, Inc. (DSGN) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Design Therapeutics, Inc. (DSGN) has an earnings quality ratio of 0.78x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.